BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation

BRAF and MEK inhibitor (BRAFi/MEKi) combinations are currently the standard treatment for patients with BRAF(V600) mutant metastatic melanoma. Since the RAS/RAF/MEK/ERK-pathway is crucial for the function of different immune cells, we postulated an effect on their function and thus interference with...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoyer, Stefanie, Eberlein, Valentina, Schuler, Gerold, Berking, Carola, Heinzerling, Lucie, Schaft, Niels, Dörrie, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585071/
https://www.ncbi.nlm.nih.gov/pubmed/34769379
http://dx.doi.org/10.3390/ijms222111951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585071/
https://www.ncbi.nlm.nih.gov/pubmed/34769379
http://dx.doi.org/10.3390/ijms222111951

Ejemplares similares